Solventum (NYSE:SOLV) Reaches New 52-Week High – What’s Next?

Solventum Corporation (NYSE:SOLV) shares reached a new 52-week high during trading on Monday . The stock traded as high as $90.45 and last traded at $90.4460, with a volume of 50878 shares. The stock had previously closed at $89.57.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on the company. UBS Group increased their price target on Solventum from $95.00 to $101.00 and gave the stock a “buy” rating in a research report on Thursday, August 6th. BMO Capital Markets started coverage on shares of Solventum in a research note on Wednesday, July 8th. They issued a “market perform” rating and a $81.00 price objective for the company. Piper Sandler increased their target price on shares of Solventum from $92.00 to $105.00 and gave the stock an “overweight” rating in a report on Thursday, August 6th. Stifel Nicolaus raised their target price on shares of Solventum from $90.00 to $100.00 and gave the company a “buy” rating in a research report on Thursday, August 6th. Finally, Wedbush boosted their price target on shares of Solventum from $94.00 to $101.00 and gave the company an “outperform” rating in a report on Thursday, August 6th. Eight research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $91.64.

Solventum Price Performance

The stock has a fifty day moving average price of $80.91 and a 200-day moving average price of $75.03. The firm has a market capitalization of $15.38 billion, a PE ratio of 11.04, a P/E/G ratio of 1.15 and a beta of 0.60. The company has a debt-to-equity ratio of 1.00, a quick ratio of 0.74 and a current ratio of 1.02.

Solventum (NYSE:SOLV) last issued its quarterly earnings data on Wednesday, August 5th. The company reported $2.55 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.91 by $0.64. Solventum had a net margin of 17.26% and a return on equity of 25.09%. The firm had revenue of $2.21 billion for the quarter, compared to the consensus estimate of $2.15 billion. During the same quarter in the previous year, the firm earned $1.69 EPS. The company’s quarterly revenue was up 2.2% compared to the same quarter last year. Solventum has set its FY 2026 guidance at 7.100-7.200 EPS. Sell-side analysts forecast that Solventum Corporation will post 7.22 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in SOLV. US Bancorp DE grew its position in Solventum by 4.6% during the fourth quarter. US Bancorp DE now owns 444,540 shares of the company’s stock valued at $35,225,000 after buying an additional 19,400 shares during the period. Diamond Hill Capital Management LLC Investment Advisor acquired a new position in shares of Solventum in the second quarter worth about $150,066,000. Davis Selected Advisers raised its position in shares of Solventum by 12.7% in the fourth quarter. Davis Selected Advisers now owns 6,220,072 shares of the company’s stock worth $492,880,000 after acquiring an additional 702,461 shares during the period. SG Americas Securities LLC boosted its stake in shares of Solventum by 38.4% during the 1st quarter. SG Americas Securities LLC now owns 129,663 shares of the company’s stock worth $8,467,000 after acquiring an additional 35,982 shares in the last quarter. Finally, Bank of America Corp DE boosted its stake in shares of Solventum by 0.6% during the 1st quarter. Bank of America Corp DE now owns 1,432,780 shares of the company’s stock worth $93,561,000 after acquiring an additional 9,083 shares in the last quarter.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.